$20,000 of SUPERNUS PHARMACEUTICALS INC lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"issues related to the pharmaceutical industry
issues related to Medicare drug reimbursement"
You can find more data on corporate lobbying on Quiver Quantitative.
SUPN Insider Trading Activity
SUPN insiders have traded $SUPN stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $SUPN stock by insiders over the last 6 months:
- PADMANABH P. BHATT (Sr. VP of IP, CSO) has traded it 2 times. They made 0 purchases and 2 sales, selling 21,495 shares.
- CHARLES W III NEWHALL sold 10,700 shares.
- GEORGES GEMAYEL has traded it 4 times. They made 0 purchases and 4 sales, selling 38,886 shares.
- JACK A. KHATTAR (President, CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 250,000 shares.
- FREDERICK M. HUDSON sold 8,722 shares.
- FRANK MOTTOLA (SVP, Quality, GMP, Ops, IT) sold 15,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SUPN Hedge Fund Activity
We have seen 123 institutional investors add shares of SUPN stock to their portfolio, and 112 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMERICAN CENTURY COMPANIES INC added 543,270 shares (+108.3%) to their portfolio in Q3 2024
- PACER ADVISORS, INC. added 403,028 shares (+29.9%) to their portfolio in Q3 2024
- BLACKROCK, INC. removed 325,704 shares (-3.1%) from their portfolio in Q3 2024
- GOLDMAN SACHS GROUP INC added 309,304 shares (+52.4%) to their portfolio in Q3 2024
- HSBC HOLDINGS PLC added 236,354 shares (+1687.0%) to their portfolio in Q3 2024
- WOODLINE PARTNERS LP added 188,571 shares (+inf%) to their portfolio in Q3 2024
- ARMISTICE CAPITAL, LLC removed 176,000 shares (-3.3%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
